



Universiteit
Leiden
The Netherlands

Evaluation of the zebrafish embryo as an alternative model for hepatotoxicity testing

Driessen, M.

Citation

Driessen, M. (2014, December 17). *Evaluation of the zebrafish embryo as an alternative model for hepatotoxicity testing*. Retrieved from <https://hdl.handle.net/1887/30138>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/30138>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/30138> holds various files of this Leiden University dissertation

Author: Driessen, Marja

Title: Evaluation of the zebrafish embryo as an alternative model for hepatotoxicity testing

Issue Date: 2014-12-17

Nederlandse samenvatting

References

Curriculum vitae

List of publications

Nederlandse Samenvatting

Korte introductie

Mensen worden gedurende hun hele leven blootgesteld aan een veelheid van schadelijke stoffen, via zowel natuurlijke als artificiële wegen. Soms vindt blootstelling aan deze schadelijke stoffen onbewust plaats, zoals blootstelling via voedsel, door inademing of door opname via de huid, of bewust wanneer men bijvoorbeeld een medicijn inneemt. Het gebruik van medicijnen kan leiden tot schade aan het lichaam, zeker wanneer er een te hoge dosering wordt ingenomen. Door middel van toxicologisch onderzoek probeert men de risico's in te schatten van deze schadelijke stoffen.

Bij toxicologisch onderzoek is de lever een belangrijk orgaan. Dit komt onder andere door de rol die de lever in het menselijk lichaam heeft. De lever komt als eerste in aanraking met giftige stoffen, nadat deze door de darm zijn opgenomen. Verder speelt de lever een rol in het omzetten van giftige stoffen naar mindere giftige stoffen die gemakkelijk door het lichaam zijn uit te scheiden. Dit proces verloopt normaal gesproken zonder problemen, maar soms kan deze omzetting van stoffen juist tot een giftiger product leiden waardoor de lever schade oploopt.

Leverschade kan resulteren in een verscheidenheid aan histopathologische veranderingen, waarbij cholestase, steatose en necrose de drie belangrijkste afwijkingen zijn. Cholestase is te zien in de levercel als geel-oranje druppeltjes. Steatose wordt gekenmerkt door ophoping van vet in de levercel en wordt zichtbaar door middel van histopathologische kleuringen. Bij necrose is er sprake van versterf van levercellen, wat afhankelijk van het stadium zichtbaar is als verkleuring of verval van levercellen. Alle vormen van leverschade kunnen uiteindelijk resulteren in leverfalen.

Om te kunnen voorspellen welke giftige stoffen tot leverschade leiden, wordt er gebruik gemaakt van zowel *in vitro* als *in vivo* modellen. Bij *in vitro* modellen analyseert men de effecten van schadelijke stoffen op cellijnen, schijfjes lever en primaire lever cellen. *In vivo* modellen richten zich op het testen van stoffen in dieren, en daarbij worden er voornamelijk muizen en ratten gebruikt. Aan deze *in vivo* dierstudies kleven een aantal ethische, economische en wetenschappelijke bezwaren. Er worden veel dieren gebruikt die voor langere tijd aan hoge doseringen van de giftige stoffen worden blootgesteld. Het belangrijkste bezwaar is echter dat de resultaten die met deze dierstudies worden behaald, lang niet altijd de situatie in de mens goed voorspellen. Dit wordt ook wel aangeduid als vals positieve of vals negatieve resultaten. Daardoor heeft het onderzoek de afgelopen jaren zich voornamelijk gefocust op de ontwikkeling van alternatieve testmethoden die de situatie in de mens beter kunnen voorspellen.

Een mogelijk goed alternatief model is het zebravis embryo model. Dit model combineert verschillende voordelen, waarvan er één is dat deze embryo's nog zo'n primitief zenuwstelsel hebben dat niet wordt verwacht dat ze pijn of ongerief kunnen ervaren. Zebravis embryo's worden daarom niet gezien als proefdier en het model draagt op die manier bij

aan de drie V strategie (Vermindering, Vervanging en Verfijning van proefdiergebruik). Normaal gesproken word het effect van de giftige stoffen bepaald door het bekijken van histopathologische veranderingen en meten van leverenzymen. Deze methoden geven echter geen informatie over het mechanisme dat leidt tot leverschade, terwijl juist dit moleculaire mechanisme mogelijkheden geeft om leverschade goed te voorspellen. Om dit onderliggende mechanisme te kunnen begrijpen, wordt er gebruik gemaakt van verschillende moleculaire technieken, gericht op analyse van met name gen- en eiwitexpressie.

Dit proefschrift beschrijft hoe het zebraavis embryo model in combinatie met gen-expressie analyse-technieken het beste gebruikt kan worden om leverschade in de mens te kunnen voorspellen.

Samenvatting van de studies beschreven in dit proefschrift

Hoofdstuk 2 beschrijft twee technieken die gebruikt zijn om te bepalen of het zebraavis embryo als alternatief model gebruikt kan worden bij de voorspelling van leverschade. Hierbij hebben we veranderingen in extracten van het gehele embryo vergeleken met veranderingen in de lever van de volwassen zebraavis, om de vraag te beantwoorden of effecten op de lever wel in het zebraavis embryo gemeten kunnen worden. Allereerst hebben we met behulp van histologie gekeken of er daadwerkelijk morfologische veranderingen in de lever van zowel de volwassen zebraavis als de embryo waargenomen kunnen worden. Hieruit kwam naar voren dat er leeftijd- en stofspecifieke veranderingen optraden in beide modellen. Daarna hebben we met behulp van next generation sequencing onderzocht of we in staat waren om genexpressie veranderingen in het embryo te kunnen waarnemen, omdat de lever maar in geringe plaats inneemt in het embryo. Na analyse kwam naar voren dat we in staat zijn om leverspecifieke veranderingen waar te nemen in het gehele embryo.

Omdat we in staat waren lever- geassocieerde genexpressie te kunnen bepalen in het gehele embryo, hebben we in **hoofdstuk 3** geanalyseerd of het mogelijk is om op basis van genexpressie profielen (transcriptomics) onderscheid te maken tussen de verschillende typen leverschade. Voor deze studie hebben we gebruik gemaakt van dezelfde stoffen als in **hoofdstuk 2**, maar zijn de genexpressie profielen op een andere manier geanalyseerd, namelijk met behulp van microarrays. Het bleek dat in het zebraavis embryo model op die manier de verschillende klassen van leverschade niet te onderscheiden zijn, omdat de genexpressie profielen van alle klassen veel overlappen. Wel bleek het mogelijk om genexpressie markers te identificeren die leverschade zouden kunnen voorspellen in de mens.

Omdat met genexpressie geen onderscheid gemaakt kon worden tussen de verschillende typen leverschade hebben we in **hoofdstuk 4** gebruik gemaakt van een andere techniek,

namelijk het meten van eiwitexpressie veranderingen (proteomics). Maar ook met deze techniek bleek het niet mogelijk om in het zebraavis embryo model onderscheid te maken tussen de verschillende typen klassen van leverschade. Daarentegen waren we wel in staat om een kleine lijst met markers te selecteren die leverschade in de mens zouden kunnen voorspellen.

Om echt de voorspellende waarde van het zebraavis embryo model te kunnen definiëren, hebben we in **hoofdstuk 5** een overkoepelende analyse uitgevoerd die de genexpressie profielen van de verschillende testmodellen voor leverschade vergelijkt. In plaats van alleen te kijken naar veranderingen in expressie van alleen genen, hebben we bestudeerd of groepen van genen, de zogenaamde pathways, veranderde na blootstelling. Uit deze vergelijking bleek dat het zebraavis embryo model met betrekking tot gereguleerde pathways overlap heeft met zowel de *in vivo* als de *in vitro* modellen. Wanneer we alle modellen met elkaar vergelijken, zowel *in vivo* als *in vitro*, komt er één pathway naar voren die in alle modellen gereguleerd is.

In de afsluitende discussie (**hoofdstuk 6**) van het proefschrift worden de voor- en nadelen van de gebruikte technieken beschouwd, en besproken welke aanvullende studies nodig zijn om het zebraavisembryo model daadwerkelijk in te zetten voor het voorspellen van leverschade door chemische stoffen in de mens. Als slotconclusie wordt geconcludeerd dat het zebraavis embryo model gebruikt kan worden als alternatief voor dierproeven bij het voorspellen van leverschade in de mens.

References

1. Zimmerman, H. J. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. (1999).
2. Olson, H. *et al.* Concordance of the toxicity of pharmaceuticals in humans and in animals. *Regul Toxicol Pharmacol* **32**, 56–67 (2000).
3. Niesink, R. J. M., De Vries, J. & Hollinger, M. A. *Toxicology*. (CRC Press LLC, 1996).
4. Jaeschke, H. *et al.* Mechanisms of hepatotoxicity. *Toxicol. Sci. Off. J. Soc. Toxicol.* **65**, 166–176 (2002).
5. Kienhuis, A. S. *et al.* Application of toxicogenomics in hepatic systems toxicology for risk assessment: Acetaminophen as a case study. *Toxicol. Appl. Pharmacol.* **250**, 96–107 (2011).
6. Lee, W. M. Drug-induced hepatotoxicity. *N. Engl. J. Med.* **349**, 474–485 (2003).
7. Godoy, P. *et al.* Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. *Arch. Toxicol.* **87**, 1315–1530 (2013).
8. Laskin, D. L. Sinusoidal Lining Cells and Hepatotoxicity. *Toxicol. Pathol.* **24**, 112–118 (1996).
9. Kolios, G., Valatas, V., Kouroumalis, E. & others. Role of Kupffer cells in the pathogenesis of liver disease. *World J. Gastroenterol.* **12**, 7413 (2006).
10. Roberts, R. A. *et al.* Role of the Kupffer Cell in Mediating Hepatic Toxicity and Carcinogenesis. *Toxicol. Sci.* **96**, 2–15 (2007).
11. Sahu, S. C. Hepatotoxicity: From Genomics to in vitro and in vivo Models. (2008).
12. Wagner, M., Zollner, G. & Trauner, M. Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. *Semin. Liver Dis.* **30**, 160–177 (2010).
13. Zollner, G. & Trauner, M. Mechanisms of cholestasis. *Clin. Liver Dis.* **12**, 1–26–vii (2008).
14. Zollner, G. & Trauner, M. Molecular mechanisms of cholestasis. *Wien. Med. Wochenschr. 1946* **156**, 380–385 (2006).
15. Yamamoto, Y. *et al.* Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. *J. Biol. Chem.* **281**, 16625–16631 (2006).
16. Anthérieu, S. *et al.* Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells. *Hepatology* **57**, 1518–1529 (2013).
17. Van Summeren, A. *et al.* Screening for drug-induced hepatotoxicity in primary mouse hepatocytes using acetaminophen, amiodarone, and cyclosporin a as model compounds: an omics-guided approach. *Omics J. Integr. Biol.* **17**, 71–83 (2013).
18. Jansen, P. L., Müller, M. & Sturm, E. Genes and cholestasis. *Hepatol. Baltim. Md* **34**, 1067–1074 (2001).
19. Anderson, N. & Borlak, J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. *Pharmacol. Rev.* **60**, 311–357 (2008).
20. McCarthy, T. C., Pollak, P. T., Hanniman, E. A. & Sinal, C. J. Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation. *J. Pharmacol. Exp. Ther.* **311**, 864–873 (2004).
21. Anthérieu, S., Rogue, A., Fromenty, B., Guillouzo, A. & Robin, M.-A. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. *Hepatol. Baltim. Md* **53**, 1895–1905 (2011).
22. Yin, H.-Q. *et al.* Hepatic gene expression profiling and lipid homeostasis in mice exposed to steatogenic drug, tetracycline. *Toxicol. Sci. Off. J. Soc. Toxicol.* **94**, 206–216 (2006).
23. Silva, M. F. B. *et al.* Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. *J. Inherit. Metab. Dis.* **31**, 205–216 (2008).
24. Lee, M.-H. *et al.* Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver. *Toxicol. Appl. Pharmacol.* **226**, 271–284 (2008).
25. Lee, M.-H. *et al.* Gene expression profiles of murine fatty liver induced by the administration of valproic acid. *Toxicol. Appl. Pharmacol.* **220**, 45–59 (2007).
26. Matsuzaka, T. & Shimano, H. Molecular mechanisms involved in hepatic steatosis and insulin resistance. *J. Diabetes Investig.* **2**, 170–175 (2011).
27. Kim, J.-S., He, L. & Lemasters, J. J. Mitochondrial permeability transition: a common pathway to necrosis and apoptosis. *Biochem. Biophys. Res. Commun.* **304**, 463–470 (2003).

28. McGill, M. R. *et al.* The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. *J. Clin. Invest.* **122**, 1574–1583 (2012).
29. McGill, M. R. & Jaeschke, H. Mechanistic biomarkers in acetaminophen-induced hepatotoxicity and acute liver failure: from preclinical models to patients. *Expert Opin. Drug Metab. Toxicol.* **10**, 1005–1017 (2014).
30. Bus, J. S. & Gibson, J. E. Paraquat: model for oxidant-initiated toxicity. *Environ. Health Perspect.* **55**, 37–46 (1984).
31. Hunter, A., Holscher, M. & Neal, R. Thioacetamide-induced hepatic necrosis I. Involvement of the mixed-function oxidase enzyme system. (1976).
32. Hinson, J. A., Roberts, D. W. & James, L. P. Mechanisms of acetaminophen-induced liver necrosis. *Handb. Exp. Pharmacol.* 369–405 (2010). doi:10.1007/978-3-642-00663-0_12
33. Jaeschke, H., McGill, M. R. & Ramachandran, A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. *Drug Metab. Rev.* **44**, 88–106 (2012).
34. Wagner, M., Zollner, G. & Trauner, M. New molecular insights into the mechanisms of cholestasis. *J. Hepatol.* **51**, 565–580 (2009).
35. McGill, M. R., Williams, C. D., Xie, Y., Ramachandran, A. & Jaeschke, H. Acetaminophen-induced liver injury in rats and mice: comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicity. *Toxicol. Appl. Pharmacol.* **264**, 387–394 (2012).
36. Burk, R. F., Lawrence, R. A. & Lane, J. M. Liver necrosis and lipid peroxidation in the rat as the result of paraquat and diquat administration: Effect of selenium deficiency. *J. Clin. Invest.* **65**, 1024 (1980).
37. Guillouzo, A. Liver cell models in in vitro toxicology. *Environ. Health Perspect.* **106 Suppl 2**, 511–532 (1998).
38. Tolosa, L., Donato, M. T., Pérez-Cataldo, G., Castell, J. V. & Gómez-Lechón, M. J. Upgrading cytochrome P450 activity in HepG2 cells co-transfected with adenoviral vectors for drug hepatotoxicity assessment. *Toxicol. In Vitro* **26**, 1272–1277 (2012).
39. Aninat, C. *et al.* Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. *Drug Metab. Dispos. Biol. Fate Chem.* **34**, 75–83 (2006).
40. Guillouzo, A. *et al.* The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. *Chem Biol Interact* **168**, 66–73 (2007).
41. McGill, M. R. *et al.* HepaRG cells: A human model to study mechanisms of acetaminophen hepatotoxicity. *Hepatol. Baltim. Md* **53**, 974–982 (2011).
42. Ramaiahgari, S. C. *et al.* A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies. *Arch. Toxicol.* (2014). doi:10.1007/s00204-014-1215-9
43. Farkas, D. & Tannenbaum, S. R. In vitro methods to study chemically-induced hepatotoxicity: a literature review. *Curr. Drug Metab.* **6**, 111–125 (2005).
44. Chu, J. & Sadler, K. C. New school in liver development: Lessons from zebrafish. *Hepatol. Baltim. Md* **50**, 1656–1663 (2009).
45. Crawford, A. D., Esguerra, C. V. & de Witte, P. A. M. Fishing for drugs from nature: zebrafish as a technology platform for natural product discovery. *Planta Med.* **74**, 624–632 (2008).
46. Hill, A., Mesens, N., Steemans, M., Xu, J. J. & Aleo, M. D. Comparisons between in vitro whole cell imaging and in vivo zebrafish-based approaches for identifying potential human hepatotoxicants earlier in pharmaceutical development. *Drug Metab. Rev.* **44**, 127–140 (2012).
47. Hill, A. J., Teraoka, H., Heideman, W. & Peterson, R. E. Zebrafish as a model vertebrate for investigating chemical toxicity. *Toxicol. Sci. Off. J. Soc. Toxicol.* **86**, 6–19 (2005).
48. Hölttä Vuori, M. *et al.* Zebrafish: gaining popularity in lipid research. *Biochem. J.* **429**, 235–242 (2010).
49. Jones, M., Ball, J. S., Dodd, A. & Hill, A. J. Comparison between zebrafish and Hep G2 assays for the predictive identification of hepatotoxins. *Toxicology* (2009).
50. Barros, T. P., Alderton, W. K., Reynolds, H. M., Roach, A. G. & Berghmans, S. Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. *Br. J. Pharmacol.* **154**, 1400–1413 (2008).
51. Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. & Schilling, T. F. Stages of embryonic development of the zebrafish. *Dev. Dyn.* **203**, 253–310 (2005).
52. Streisinger, G., Walker, C., Dower, N., Knauber, D. & Singer, F. Production of clones of homozygous diploid zebra fish (*Brachydanio rerio*). *Nature* **291**, 293–296 (1981).
53. Yang, L. *et al.* Transcriptional profiling reveals barcode-like toxicogenomic responses in the zebrafish embryo. *Genome Biol* **8**, R227 (2007).
54. Sukardi, H., Chng, H. T., Chan, E. C. Y., Gong, Z. & Lam, S. H. Zebrafish for drug toxicity screening: bridging the in vitro cell-based models and in vivo mammalian models. *Expert Opin. Drug Metab. Toxicol.* **7**, 579–589 (2011).
55. Goldstone, J. V. *et al.* Identification and developmental expression of the full complement of Cytochrome P450 genes in Zebrafish. *BMC Genomics* **11**, 643 (2010).
56. McGrath, P. & Li, C.-Q. Zebrafish: a predictive model for assessing drug-induced toxicity. *Drug Discov. Today* **13**, 394–401 (2008).
57. Amali, A. A. *et al.* Thioacetamide induced liver damage in zebrafish embryo as a disease model for steatohepatitis. *J. Biomed. Sci.* **13**, 225–232 (2006).
58. Sawle, A. D., Wit, E., Whale, G. & Cossins, A. R. An Information-Rich Alternative, Chemicals Testing Strategy Using a High Definition Toxicogenomics and Zebrafish (*Danio rerio*) Embryos. *Toxicol. Sci.* **118**, 128–139 (2010).
59. Delvecchio, C., Tiefenbach, J. & Krause, H. M. The Zebrafish: A Powerful Platform for *In Vivo*, HTS Drug Discovery. *ASSAY Drug Dev. Technol.* **9**, 354–361 (2011).
60. Soldatow, V. Y., LeCluyse, E. L., Griffith, L. G. & Rusyn, I. In vitro models for liver toxicity testing. *Toxicol. Res.* **2**, 23 (2013).
61. Blomme, E. A. G., Yang, Y. & Waring, J. F. Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. *Toxicol. Lett.* **186**, 22–31 (2009).
62. Aubrecht, J., Schomaker, S. J. & Amacher, D. E. Emerging hepatotoxicity biomarkers and their potential to improve understanding and management of drug-induced liver injury. *Genome Med.* **5**, 85 (2013).
63. Zhang, M., Chen, M. & Tong, W. Is Toxicogenomics a More Reliable and Sensitive Biomarker than Conventional Indicators from Rats To Predict Drug-Induced Liver Injury in Humans? *Chem. Res. Toxicol.* **25**, 122–129 (2012).
64. Chen, M., Zhang, M., Borlak, J. & Tong, W. A decade of toxicogenomic research and its contribution to toxicological science. *Toxicol. Sci.* kfs223 (2012).
65. Chen, M. *et al.* Toward predictive models for drug-induced liver injury in humans: are we there yet? *Biomark. Med.* **8**, 201–213 (2014).
66. Hermesen, S. A., van den Brandhof, E. J., van der Ven, L. T. & Piersma, A. H. Relative embryotoxicity of two classes of chemicals in a modified zebrafish embryotoxicity test and comparison with their in vivo potencies. *Toxicol. Vitro* **25**, 745–753 (2011).
67. Hermesen, S. A. B., Pronk, T. E., van den Brandhof, E.-J., van der Ven, L. T. M. & Piersma, A. H. Transcriptomic analysis in the developing zebrafish embryo after compound exposure: individual gene expression and pathway regulation. *Toxicol. Appl. Pharmacol.* **272**, 161–171 (2013).
68. Hermesen, S. A. B., Pronk, T. E., van den Brandhof, E.-J., van der Ven, L. T. M. & Piersma, A. H. Concentration-response analysis of differential gene expression in the zebrafish embryotoxicity test following flusilazole exposure. *Toxicol. Sci. Off. J. Soc. Toxicol.* **127**, 303–312 (2012).
69. Hermesen, S. A. B., Pronk, T. E., van den Brandhof, E.-J., van der Ven, L. T. M. & Piersma, A. H. Triazole-induced gene expression changes in the zebrafish embryo. *Reprod. Toxicol. Elmsford N* **34**, 216–224 (2012).
70. Hermesen, S. A. B., Pronk, T. E., van den Brandhof, E.-J., van der Ven, L. T. M. & Piersma, A. H. Chemical class-specific gene expression changes in the zebrafish embryo after exposure to glycol ether alkoxy acids and 1,2,4-triazole antifungals. *Reprod. Toxicol. Elmsford N* **32**, 245–252 (2011).
71. Van Summeren, A., Renes, J., van Delft, J. H. M., Kleinjans, J. C. S. & Mariman, E. C. M. Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity. *Toxicol. Vitro* **26**, 373–385 (2012).
72. Van Summeren, A. *et al.* Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. *Toxicol. Sci. Off. J. Soc. Toxicol.* **120**, 109–122 (2011).
73. Voelker, D. *et al.* Differential gene expression as a toxicant-sensitive endpoint in zebrafish embryos and larvae. *Aquat. Toxicol.* **81**, 355–364 (2007).
74. Quackenbush, J. Microarray data normalization and transformation. *Nat. Genet.* **32**, 496–501 (2002).
75. Irizarry, R. A. *et al.* Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostat. Oxf. Engl.* **4**, 249–264 (2003).
76. Irizarry, R. A. *et al.* Summaries of Affymetrix GeneChip probe level data. *Nucleic Acids Res* **31**, e15 (2003).
77. Ashburner, M. *et al.* Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat. Genet.* **25**, 25–29 (2000).

78. Apweiler, R. *et al.* UniProt: the Universal Protein knowledgebase. *Nucleic Acids Res.* **32**, D115–119 (2004).
79. Magrane, M. & Consortium, U. UniProt Knowledgebase: a hub of integrated protein data. *Database J. Biol. Databases Curation* **2011**, bar009 (2011).
80. NCBI Resource Coordinators. Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res.* **42**, D7–17 (2014).
81. Davis, A. P. *et al.* The Comparative Toxicogenomics Database: update 2013. *Nucleic Acids Res.* **41**, D1104–1114 (2013).
82. Bradford, Y. *et al.* ZFIN: enhancements and updates to the zebrafish model organism database. *Nucleic Acids Res* **1**, D822–D829 (2011).
83. Boorsma, A., Foat, B. C., Vis, D., Klis, F. & Bussemaker, H. J. T-profiler: scoring the activity of predefined groups of genes using gene expression data. *Nucleic Acids Res.* **33**, W592–5 (2005).
84. Da Wei Huang, Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* **4**, 44–57 (2008).
85. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* **37**, 1–13 (2009).
86. Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* **28**, 27–30 (2000).
87. Kanehisa, M. *et al.* Data, information, knowledge and principle: back to metabolism in KEGG. *Nucleic Acids Res* **42**, D199–205 (2014).
88. Kelder, T. *et al.* WikiPathways: building research communities on biological pathways. *Nucleic Acids Res* **40**, D1301–7 (2012).
89. Kelder, T. *et al.* Mining biological pathways using WikiPathways web services. *PLoS ONE* **4**, e6447 (2009).
90. Keller, A., Eng, J., Zhang, N., Li, X. & Aebersold, R. A uniform proteomics MS/MS analysis platform utilizing open XML file formats. *Mol. Syst. Biol.* **1**, 2005.0017 (2005).
91. Kuhn, M. *et al.* STITCH 4: integration of protein-chemical interactions with user data. *Nucleic Acids Res.* **42**, D401–407 (2014).
92. Kuhn, M. *et al.* STITCH 3: zooming in on protein-chemical interactions. *Nucleic Acids Res.* **40**, D876–880 (2012).
93. Kuhn, M. *et al.* STITCH 2: an interaction network database for small molecules and proteins. *Nucleic Acids Res.* **38**, D552–556 (2010).
94. Kuhn, M., von Mering, C., Campillos, M., Jensen, L. J. & Bork, P. STITCH: interaction networks of chemicals and proteins. *Nucleic Acids Res.* **36**, D684–688 (2008).
95. Peterson, R. T. & Macrae, C. A. Systematic approaches to toxicology in the zebrafish. *Annu. Rev. Pharmacol. Toxicol.* **52**, 433–453 (2012).
96. ELFERINK, M. *et al.* Microarray analysis in rat liver slices correctly predicts in vivo hepatotoxicity. *Toxicol. Appl. Pharmacol.* **229**, 300–309 (2008).
97. Kienhuis, A. S. *et al.* A toxicogenomics-based parallelogram approach to evaluate the relevance of coumarin-induced responses in primary human hepatocytes in vitro for humans in vivo. *Toxicol Vitro* **23**, 1163–1169 (2009).
98. Kienhuis, A. S. *et al.* Parallelogram approach using rat-human in vitro and rat in vivo toxicogenomics predicts acetaminophen-induced hepatotoxicity in humans. *Toxicol. Sci. Off. J. Soc. Toxicol.* **107**, 544–552 (2009).
99. Schoonen, W. G., de Roos, J. A., Westerink, W. M. & Debiton, E. Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. II mechanistic assays on NAD(P)H, ATP and DNA contents. *Toxicol Vitro* **19**, 491–503 (2005).
100. Schoonen, W. G. E. J., Westerink, W. M. A., de Roos, J. A. D. M. & Débiton, E. Cytotoxic effects of 100 reference compounds on Hep G2 and HeLa cells and of 60 compounds on ECC-1 and CHO cells. I Mechanistic assays on ROS, glutathione depletion and calcein uptake. *Toxicol. In Vitro* **19**, 505–516 (2005).
101. Boess, F. *et al.* Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. *Toxicol. Sci. Off. J. Soc. Toxicol.* **73**, 386–402 (2003).
102. Dooley, K., Dooley, K. & Zon, L. I. Zebrafish: a model system for the study of human disease. *Curr Opin Genet Dev* **10**, 252–256 (2000).
103. Zon, L. I. & Peterson, R. T. In vivo drug discovery in the zebrafish. *Nat Rev Drug Discov* **4**, 35–44 (2005).
104. EFSA. Opinion of the Scientific Panel on Animal Health and Welfare on a request from the Commission related to 'Aspects of the biology and welfare of animals used for experimental and other scientific purposes'. *EFSA J.* **292**, 1–46 (2005).
105. Alderton, W. *et al.* Accumulation and metabolism of drugs and CYP probe substrates in zebrafish larvae. *Xenobiotica* **40**, 547–557 (2010).
106. Pronk, T. E., van der Veen, J. W., Ezendam, J., Van Loveren, H. & Pennings, J. L. A. Effects of pooling RNA from samples treated with different compounds for determining class specific biomarkers and processes in toxicogenomics. *Toxicol. In Vitro* **25**, 1841–1847 (2011).
107. 't Hoen, P. A. *et al.* Deep sequencing-based expression analysis shows major advances in robustness, resolution and inter-lab portability over five microarray platforms. *Nucleic Acids Res* **36**, e141 (2008).
108. Sabaliauskas, N. A. *et al.* High-throughput zebrafish histology. *Methods San Diego Calif* **39**, 246–254 (2006).
109. Tsao-Wu, G. S., Weber, C. H., Budgeon, L. R. & Cheng, K. C. *Agarose-embedded tissue arrays for histologic and genetic analysis.* 614–618 (1998).
110. De Jong, M. *et al.* RNA isolation method for single embryo transcriptome analysis in zebrafish. *BMC Res Notes* **3**, 73 (2010).
111. Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat Methods* **5**, 621–628 (2008).
112. Hegedűs, Z. *et al.* Deep sequencing of the zebrafish transcriptome response to mycobacterium infection. *Mol. Immunol.* **46**, 2918–2930 (2009).
113. Ordas, A. *et al.* Deep sequencing of the innate immune transcriptomic response of zebrafish embryos to Salmonella infection. *Fish Amp Shellfish Immunol.* **31**, 716–724 (2011).
114. Stockhammer, O. W. *et al.* Transcriptome analysis of Traf6 function in the innate immune response of zebrafish embryos. *Mol. Immunol.* **48**, 179–190 (2010).
115. Jelier, R. *et al.* Anni 2.0: a multipurpose text-mining tool for the life sciences. *Genome Biol* **9**, R96 (2008).
116. Van Iersel, M. P. *et al.* Presenting and exploring biological pathways with PathVisio. *BMC Bioinformatics* (2008). doi:10.1186/1471-2105-9-399
117. Barbazuk, W. B. *et al.* The syntenic relationship of the zebrafish and human genomes. *Genome Res* **10**, 1351–1358 (2000).
118. Dai, M. *et al.* Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. *Nucleic Acids Res.* **33**, e175–e175 (2005).
119. Kienhuis, A. S. *et al.* Cyclosporine A treated in vitro models induce cholestasis response through comparison of phenotype-directed gene expression analysis of in vivo Cyclosporine A-induced cholestasis. *Toxicol. Lett.* **221**, 225–236 (2013).
120. Jennen, D. G. J. *et al.* Comparison of HepG2 and HepaRG by Whole-Genome Gene Expression Analysis for the Purpose of Chemical Hazard Identification. *Toxicol. Sci.* **115**, 66–79 (2010).
121. Liberzon, A. *et al.* Molecular signatures database (MSigDB) 3.0. *Bioinformatics* **27**, 1740
122. Rozen, S. & Skaletsky, H. Primer3 on the WWW for general users and for biologist programmers. *Methods Mol Biol* **132**, 365–386 (2000).
123. Flynn, E. J., Trent, C. M. & Rawls, J. F. Ontogeny and nutritional control of adipogenesis in zebrafish (*Danio rerio*). *J. Lipid Res.* **50**, 1641–1652 (2009).
124. Thisse, C. & Thisse, B. High-resolution in situ hybridization to whole-mount zebrafish embryos. *Nat Protoc* **3**, 59–69 (2008).
125. Hibiya, T. *et al.* *An Atlas of Fish Histology Normal and Pathological Features.* (Kodansha LTD, 21-21 Otowa 2-chome, Bunkyo-ku, Tokyo 112, Japan, 1982).
126. Tao, T. & Peng, J. Liver development in zebrafish (*Danio rerio*). *J. Genet. Genomics* **36**, 325–334 (2009).
127. Strmac, M. & Braunbeck, T. Effects of Triphenyltin Acetate on Survival, Hatching Success, and Liver Ultrastructure of Early Life Stages of Zebrafish (*Danio rerio*). *Ecotoxicol. Environ. Saf.* **44**, 25–39 (1999).
128. Reynaud, S., Raveton, M. & Ravanel, P. Interactions between immune and biotransformation systems in fish: a review. *Aquat Toxicol* **87**, 139–145 (2008).
129. JONSSON, M., Orrego, R., WOODIN, B., GOLDSTONE, J. & STEGEMAN, J. Basal and 3,3',4,4',5-pentachlorobiphenyl-induced expression of cytochrome P450 1A, 1B and 1C genes in zebrafish. *Toxicol. Appl. Pharmacol.* **221**, 29–41 (2007).

130. Ryu, J. *et al.* Molecular cloning of cytochrome P4501A cDNA of medaka (*Oryzias latipes*) and messenger ribonucleic acid regulation by environmental pollutants. *Env. Toxicol Chem* **23**, 1004–1011 (2004).
131. Sharma, M. K. *et al.* Hierarchical subfunctionalization of fabp1a, fabp1b and fabp10 tissue-specific expression may account for retention of these duplicated genes in the zebrafish (*Danio rerio*) genome. *FEBS J.* **273**, 3216–3229 (2006).
132. Vaziri, N. D., Liang, K. & Azad, H. Effect of cyclosporine on HMG-CoA reductase, cholesterol 7 α -hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions. *J Pharmacol Exp Ther* **294**, 778–783 (2000).
133. Driessen, M. *et al.* Exploring the zebrafish embryo as an alternative model for the evaluation of liver toxicity by histopathology and expression profiling. *Arch. Toxicol.* **87**, 807–823 (2013).
134. Ansele, J. H., Smith, W. R., Perry, C. H., St Claire, R. L. & Brouwer, K. R. An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes. *Drug Metab. Dispos. Biol. Fate Chem.* **38**, 276–280 (2010).
135. Bohan, A. & Boyer, J. L. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. *Semin. Liver Dis.* **22**, 123–136 (2002).
136. Leitner, J. M., Graninger, W. & Thalhammer, F. Hepatotoxicity of antibacterials: Pathomechanisms and clinical. *Infection* **38**, 3–11 (2010).
137. Santangeli, P. *et al.* Examining the safety of amiodarone. *Expert Opin. Drug Saf.* **11**, 191–214 (2012).
138. Jaeschke, H., Knight, T. R. & Bajt, M. L. The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity. *Toxicol. Lett.* **144**, 279–288 (2003).
139. DeLeve, L. D. & Kaplowitz, N. Glutathione metabolism and its role in hepatotoxicity. *Pharmacol. Amp Ther.* **52**, 287–305 (1991).
140. Ellinger-Ziegelbauer, H. *et al.* The enhanced value of combining conventional and “omics” analyses in early assessment of drug-induced hepatobiliary injury. *Toxicol. Appl. Pharmacol.* **252**, 97–111 (2011).
141. Vitins, A. P. *et al.* Mechanisms of amiodarone and valproic acid induced liver steatosis in mouse in vivo act as a template for other hepatotoxicity models. *Arch. Toxicol.* 1–16 (2014). doi:10.1007/s00204-014-1211-0
142. Nciri, R. *et al.* Lipid peroxidation, antioxidant activities and stress protein (HSP72/73, GRP94) expression in kidney and liver of rats under lithium treatment. *J. Physiol. Biochem.* **68**, 11–18 (2012).
143. Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. *Oncogene* **22**, 7265–7279 (2003).
144. Serviddio, G. *et al.* Mitochondrial oxidative stress and respiratory chain dysfunction account for liver toxicity during amiodarone but not dronedarone administration. *Free Radic. Biol. Amp Med.* **51**, 2234–2242 (2011).
145. Tsukamoto, M., Tampo, Y., Sawada, M. & Yonaha, M. Paraquat-induced oxidative stress and dysfunction of the glutathione redox cycle in pulmonary microvascular endothelial cells. *Toxicol Appl Pharmacol* **178**, 82–92 (2002).
146. Zidek, N., Hellmann, J., Kramer, P.-J. & Hewitt, P. G. Acute hepatotoxicity: a predictive model based on focused illumina microarrays. *Toxicol. Sci. Off. J. Soc. Toxicol.* **99**, 289–302 (2007).
147. Chang, C. *et al.* liver-enriched gene 1a and 1b encode novel secretory proteins essential for normal liver development in zebrafish. *PLoS ONE* **6**, e22910 (2011).
148. Baginsky, S., Hennig, L., Zimmermann, P. & Grussem, W. Gene Expression Analysis, Proteomics, and Network Discovery. *Plant Physiol.* **152**, 402–410 (2010).
149. Driessen, M. *et al.* Gene expression markers in the zebrafish embryo reflect a hepatotoxic response in animal models and humans. *Toxicol. Lett.* doi:10.1016/j.toxlet.2014.06.844
150. Van der Plas-Duivesteyn, S. J. *et al.* Identifying Proteins in Zebrafish Embryos Using Spectral Libraries Generated from Dissected Adult Organs and Tissues. *J. Proteome Res.*
151. Pedrioli, P. G. A. *et al.* A common open representation of mass spectrometry data and its application to proteomics research. *Nat. Biotechnol.* **22**, 1459–1466 (2004).
152. Deutsch, E. W. *et al.* A guided tour of the Trans-Proteomic Pipeline. *Proteomics* **10**, 1150–1159 (2010).
153. Craig, R. & Beavis, R. C. TANDEM: matching proteins with tandem mass spectra. *Bioinformatics* (2004). doi:10.1093/bioinformatics/bth092
154. Keller, A., Nesvizhskii, A. I., Kolker, E. & Aebersold, R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. *Anal. Chem.* **74**, 5383–5392 (2002).
155. Shteynberg, D. *et al.* iProphet: multi-level integrative analysis of shotgun proteomic data improves peptide and protein identification rates and error estimates. *Mol. Cell. Proteomics MCP* **10**, M111.007690 (2011).
156. Palmblad, M. *et al.* Parallel deep transcriptome and proteome analysis of zebrafish larvae. *BMC Res Notes* **6**, 428 (2013).
157. Paschen, W., Proud, C. G. & Mies, G. Shut-down of translation, a global neuronal stress response: mechanisms and pathological relevance. *Curr. Pharm. Des.* **13**, 1887–1902 (2007).
158. Fribley, A., Zhang, K. & Kaufman, R. J. Regulation of Apoptosis by the Unfolded Protein Response. *Methods Mol. Biol. Clifton NJ* **559**, 191–204 (2009).
159. Fredriksson, L. *et al.* Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF α -mediated hepatotoxicity. *Toxicol. Sci. Off. J. Soc. Toxicol.* **140**, 144–159 (2014).
160. Hanisch, K. *et al.* Proteomic Signatures of the Zebrafish (*Danio rerio*) Embryo: Sensitivity and Specificity in Toxicity Assessment of Chemicals. *Int. J. Proteomics* **2010**, e630134 (2010).
161. Shi, X., Liu, C., Wu, G. & Zhou, B. Waterborne exposure to PFOS causes disruption of the hypothalamus-pituitary-thyroid axis in zebrafish larvae. *Chemosphere* **77**, 1010–1018 (2009).
162. Hu, Z. *et al.* Quantitative liver-specific protein fingerprint in blood: a signature for hepatotoxicity. *Theranostics* **4**, 215–228 (2014).
163. Ponnudurai, R. P. *et al.* Proteomic analysis of zebrafish (*Danio rerio*) embryos exposed to cyclosporine A. *J. Proteomics* **75**, 1004–1017 (2012).
164. Szalowska, E., Stoopen, G., Groot, M. J., Hendriksen, P. J. & Peijnenburg, A. A. Treatment of mouse liver slices with cholestatic hepatotoxicants results in down-regulation of Fxr and its target genes. *BMC Med. Genomics* **6**, 39 (2013).
165. Locatelli, I. *et al.* Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice. *Hepatology. Baltim. Md* **60**, 531–544 (2014).
166. Greenbaum, D., Colangelo, C., Williams, K. & Gerstein, M. Comparing protein abundance and mRNA expression levels on a genomic scale. *Genome Biol.* **4**, 117 (2003).
167. Vitins, A. P., Kienhuis, A. S., Speksnijder, E. N., Roodbergen, M. & der Ven, L. T. M. van. A mouse in vivo study of liver necrosis inducing chemical compounds acetaminophen, paraquat, and isoniazid identifies robust markers for the onset and progression of disease.
168. Van Summeren, A., Renes, J., Lizarraga, D., Bouwman, F. G., Noben, J.-P., van Delft, J. H. M., *et al.* (2013). Screening for drug-induced hepatotoxicity in primary mouse hepatocytes using acetaminophen, amiodarone, and cyclosporin A as model compounds: an omics-guided approach. *Omics : a Journal of Integrative Biology*, **17**(2), 71–83. doi:10.1089/omi.2012.0079.
169. Mathijs, K. *et al.* Assessing the metabolic competence of sandwich-cultured mouse primary hepatocytes. *Drug Metab. Dispos. Biol. Fate Chem.* (2009). doi:10.1124/dmd.108.025775
170. Noriyuki, N. *et al.* Evaluation of DNA microarray results in the Toxicogenomics Project (TGP) consortium in Japan. *J. Toxicol. Sci.* **37**, 791–801 (2012).
171. Uehara, T. *et al.* The Japanese toxicogenomics project: Application of toxicogenomics. *Mol. Nutr. Amp Food Res.* **54**, 218–227 (2010).
172. User-friendly solutions for microarray quality control and pre-processing on ArrayAnalysis.org. *Nucleic Acids Res* **41**, W71–6 (2013).
173. Chessel, D., Dufour, A. B. & Dray, S. *ade4: Analysis of Ecological Data: Exploratory and Euclidean methods in Multivariate data analysis and graphical display.* (R package version, 2007).
174. Dray, S. & Dufour, A. B. The ade4 package: implementing the duality diagram for ecologists. *J. Stat. Softw.* (2007).
175. Wickham, H. *ggplot2: elegant graphics for data analysis.* (2009).
176. Tomaszewski, P., Kubiak-Tomaszewska, G. & Pachecka, J. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs. *Acta Pol. Pharm.* **65**, 307–318 (2008).
177. Li, L. *et al.* Farnesoid X receptor up-regulates expression of lipid transfer inhibitor protein in liver cells and mice. *Biochem. Biophys. Res. Commun.* **441**, 880–885 (2013).
178. Jonker, J. W., Liddle, C. & Downes, M. FXR and PXR: potential therapeutic targets in cholestasis. *J. Steroid Biochem. Mol. Biol.* **130**, 147–158 (2012).
179. Campion, S. N. *et al.* Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function. *Am. J. Physiol. Gastrointest. Liver Physiol.* **295**, G294–304 (2008).

180. Groneberg, D. A., Grosse-Siestrup, C. & Fischer, A. In Vitro Models to Study Hepatotoxicity. *Toxicol. Pathol.* **30**, 394–399 (2002).
181. Stadnicka, J., Schirmer, K. & Ashauer, R. Predicting concentrations of organic chemicals in fish by using toxicokinetic models. *Environ. Sci. Technol.* **46**, 3273–3280 (2012).
182. Diekmann, H. & Hill, A. ADMETox in zebrafish. *Drug Discov. Today Dis. Models* **10**, e31–e35 (2013).
183. Stadnicka-Michalak, J., Tanneberger, K., Schirmer, K. & Ashauer, R. Measured and modeled toxicokinetics in cultured fish cells and application to in vitro-in vivo toxicity extrapolation. *PLoS One* **9**, e92303 (2014).
184. Uno, T., Ishizuka, M. & Itakura, T. Cytochrome P450 (CYP) in fish. *Environ. Toxicol. Pharmacol.* **34**, 1–13 (2012).
185. De Koning, C. *et al.* Zebrafish embryotoxicity test (ZET): the importance of internal exposure analyses. in (2014).
186. Shaukat Ali, H. G. J. van M. Large-scale assessment of the zebrafish embryo as a possible predictive model in toxicity testing. *PLoS One* **6**, e21076 (2011).
187. Scholz, S. Zebrafish embryos as an alternative model for screening of drug-induced organ toxicity. *Arch. Toxicol.* (2013). doi:10.1007/s00204-013-1044-2
188. Aleksunes, L. M. & Manautou, J. E. Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease. *Toxicol. Pathol.* **35**, 459–473 (2007).
189. Mukaigasa, K. *et al.* Genetic evidence of an evolutionarily conserved role for Nrf2 in the protection against oxidative stress. *Mol. Cell. Biol.* **32**, 4455–4461 (2012).
190. Bugel, S. M., Tanguay, R. L. & Planchart, A. Zebrafish: A Marvel of High-Throughput Biology for 21st Century Toxicology. *Curr. Environ. Health Rep.* **1**, 341–352 (2014).
191. Higashijima, S. Transgenic zebrafish expressing fluorescent proteins in central nervous system neurons. *Dev. Growth Differ.* **50**, 407–413 (2008).
192. Leet, J. K. *et al.* High-content screening in zebrafish embryos identifies butafenacil as a potent inducer of anemia. *PLoS One* **9**, e104190 (2014).
193. Sipes, N. S., Padilla, S. & Knudsen, T. B. Zebrafish: as an integrative model for twenty-first century toxicity testing. *Birth Defects Res. Part C Embryo Today Rev.* **93**, 256–267 (2011).
194. Truong, L., Mandrell, D., Mandrell, R., Simonich, M. & Tanguay, R. L. A rapid throughput approach identifies cognitive deficits in adult zebrafish from developmental exposure to polybrominated flame retardants. *Neurotoxicology* **43**, 134–142 (2014).
195. Her, G. M., Chiang, C.-C., Chen, W.-Y. & Wu, J.-L. In vivo studies of liver-type fatty acid binding protein (L-FABP) gene expression in liver of transgenic zebrafish (*Danio rerio*). *FEBS Lett.* **538**, 125–133 (2003).
196. Zhang, X., Li, C. & Gong, Z. Development of a Convenient In Vivo Hepatotoxin Assay Using a Transgenic Zebrafish Line with Liver-Specific DsRed Expression. *PLoS ONE* **9**, e91874 (2014).
197. McKim, J. M. Building a Tiered Approach to In Vitro Predictive Toxicity Screening: A Focus on Assays with In Vivo Relevance. *Comb. Chem. High Throughput Screen.* **13**, 188–206 (2010).

Curriculum Vitae

Marja Driessen was born on January 23, 1985 in Breda, The Netherlands. After graduating from secondary school at Stedelijk Lyceum in Roermond in 2003, she started her study in Health Sciences at the University of Maastricht with a major in Bioregulation & Health and a minor in Movement Sciences. During her studies, she completed several internships. Her Bachelor internship was conducted at the Academic Hospital Pharmacy in Maastricht under the supervision of Dr. Leo Stolk and Dr. Joyce Pullen. Her Master internship was performed at the Department of Tumor Immunology, Maastricht University under the supervision of Dr. Michel van Gelder and Peter Frings. After obtaining her Master degree in 2007, she applied for a second Master in Bio-Informatics at the Catholic University of Leuven, Belgium. There she conducted her internship in the Department of Electrical Engineering (ESAT) under the supervision of Prof. Dr. Bart de Moor and Tunde Adeshoyla Adefoye. After graduating in 2009, she started her PhD study on the applicability of the zebrafish embryo as a screening model for hepatotoxicity under the direct scientific supervision of Dr. Leo T.M. van der Ven and Dr. Anne. S. Kienhuis (RIVM, Laboratory for Health Protection Research). Since February 2014, Marja has a position as a postdoctoral fellow in the Structural Computational Biology Department of the European Molecular Biology Laboratory (EMBL) Heidelberg, Germany.

List of publications

Articles

Driessen M, Duijvesteijn – van der Plas S, Vitins AP, Kienhuis AS, Pennings JL, van den Brandhof EJ, Roodbergen M, van de Water B, Spaink HP, Palmblad NM, van der Ven LTM. *Toxicogenomics approach in the zebrafish embryo to assess hepatotoxicity: combination of protein and gene expression changes*. In preparation

Driessen M, Vitins AP, Pennings JL, Kienhuis AS, van de Water B, van der Ven LTM. *A transcriptomics-based hepatotoxicity comparison between the zebrafish embryo and established human and rodent in vitro and in vivo models using cyclosporine A, amiodarone and acetaminophen*. Revisions in Toxicology Letters

Driessen M, Kienhuis AS, Vitins AP, Pennings JL, Pronk TE, van den Brandhof EJ, Roodbergen M, van de Water B, van der Ven LTM. *Gene expression markers in the zebrafish embryo reflect a hepatotoxic response in animal models and humans*. Toxicology Letters, 2014 Jul 24;230(1):48-56

Driessen M, Kienhuis AS, Pennings JL, Pronk TE, van den Brandhof EJ, Roodbergen M, Spaink HP, van de Water B, van der Ven LTM. *Exploring the zebrafish embryo as an alternative model for the evaluation of liver toxicity by histopathology and expression profiling*. Archives of Toxicology 2013 May;87(5):807-23

Kienhuis AS, Bessems JG, Pennings JL, Driessen M, Luijten M, van Delft JH, Peijnenburg AA, van der LTM. *Application of toxicogenomics in hepatic systems toxicology for risk assessment: acetaminophen as a case study*. Toxicology and Applied Pharmacology. 2011 Jan 15;250(2):96-107

Pullen J, Driessen M, Stolk LM, Degraeuwe PL, van Tiel FH, Neef C and Zimmermann LJ. *Amoxicillin pharmacokinetics in (pre)term infants aged 10 to 52 days: effect of postnatal age*. Therapeutic Drugs Monitoring 2007 Jun;29(3):376-80

Book chapter

Driessen M and van der Ven, LTM. Chapter in Toxicogenomics-Based Cellular Methods, *Alternatives to Animal Testing for Safety Assessment*, 1st Edition. Academic Press, 2014 March 7 ISBN: 9780123978622

Patent

Driessen, M and van der Ven LTM. *Hepatotoxicity testing in zebrafish embryo*. Patent application number EP13165649.8 (European)